SIRT1 and metabolic dysfunction-associated steatohepatitis: SIRT1 may also curb ferroptosis in NASH by modulating other molecular pathways associated with ferroptosis, such as inhibiting lipid peroxidation and fostering iron metabolic equilibrium, offering new potential targets for NASH treatment (He et al., 2023; Yang et al., 2023).